SCWorx Corp. (WORX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, WORX scores 23 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 5 / 20. Per the Roarable RQD rating, ROIC is -10.6% and FCF yield is 0%. For an investor, this means the business is not currently generating a return on invested capital or free cash flow that would support valuation on cash-flow grounds.
• Whale 13F Flow: 3 / 20. The rating reflects institutional accumulation and options positioning. The underlying 13F detail is not itemized in the source data, but the low score indicates weak institutional support.
• Insider Conviction: 3 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates insider and political-disclosure activity does not provide a supportive signal.
• Macro Regime Fit: 7 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. The score is the highest of the five pillars but still well below half, meaning the stock's macro positioning offers limited offsetting support.
• Forensic Balance Sheet: 5 / 20. Per the Roarable RQD rating, Altman Z is 0.2, Piotroski F is 3/9, and Debt/Equity is 0.5. A low Altman Z places the company in a distress-risk zone, and a Piotroski score of 3 of 9 indicates weak financial-quality signals.

Taken together, the investor implication is that the upside case rests on a turnaround that the current cash-flow, return, and balance-sheet metrics do not yet evidence. Valuation tradeoffs are difficult to assess because P/E and EV/EBITDA are not available in the source data, and the market capitalization of $2.5M combined with the 52-week range of $1.07 - $118.26 indicates extreme price dislocation over the past year. Investors evaluating this stock should weigh the forensic risk flags as the dominant factor rather than any single pillar.

Per the SEC financials, revenue declined from $3.8M in FY 2023 to $2.9M in FY 2025, while operating losses remained in each reported year and net income was negative in all three periods. Per the market data, gross margin is 32%, operating margin is -33.3%, and net margin is -60%. Per the Roarable RQD rating, ROIC is -10.6%, and the forensic inputs show an Altman Z-Score of 0.2 and a Piotroski F-Score of 3/9, with Debt/Equity at 0.5. Cash and debt balances are not reported in the source data for any period.

Per the recent news feed, the most recent items reference a Nasdaq decision to keep SCWorx listed without a set trading restart date, a relisting event followed by stock declines, and a healthcare-data first-half loss that narrowed from about $2.4 million to about $295,000. Items flagged "RISK WATCH" concern the reported first-half loss narrowing, while the remaining items are flagged as market-wire coverage of price action around the relisting. The butterfly supply-chain graph reports no supply chain, no butterfly links, and no proprietary signals. The narrowed first-half loss is the one reported item that points to improving loss trajectory, though its full context is not in the source data.

• What are the company's specific products, customers, and revenue drivers behind the $2.9M FY 2025 revenue figure?
• What are cash, debt, and EPS figures for each reported period, since these are listed as N/A?
• What conditions and timeline apply to the Nasdaq listing decision and any trading restart?
• What drove the net loss of $-4.4M in FY 2025 relative to the $-1.5M operating loss, and is there a balance-sheet or non-operating explanation?
• What is the basis for the narrowed first-half loss reported in the news feed, and how does it reconcile with the full-year figures?